NVS owns 56% of IDIX’s shares so, realistically, there can’t be another serious suitor for IDIX. The situation is analogous to Roche-DNA, on a much smaller scale, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”